Clinical Trials Logo

Gastroesophageal Reflux clinical trials

View clinical trials related to Gastroesophageal Reflux.

Filter by:

NCT ID: NCT05701540 Recruiting - Clinical trials for Gastroesophageal Reflux Disease

A Study to Evaluate the Efficacy and Safety of Tegoprazan in GERD Patients With Nighttime Heartburn

Start date: March 24, 2023
Phase: Phase 4
Study type: Interventional

This study aims to compare the nighttime heartburn improvement effect of Tegoprazan 50mg and Esomeprazole 40mg(or 20mg) in patients with GERD.

NCT ID: NCT05697393 Recruiting - Clinical trials for Gastroesophageal Reflux

External UES Band (Shaker Pressure Band) and GERD

Start date: January 25, 2011
Phase: N/A
Study type: Interventional

This protocol is a study to assess the efficacy of an external upper esophageal band to decrease subjective nighttime symptoms related to esophageal reflux into the pharynx.

NCT ID: NCT05695846 Recruiting - Clinical trials for Gastroesophageal Reflux

Diagnostic Tests in Supra-Esophageal Gastroesophageal Reflux Disease (SE-GERD)

SE-GERD
Start date: January 29, 2014
Phase: N/A
Study type: Interventional

After defining the manometric characteristics of UES incompetence associated with documented pharyngeal reflux, we will determine the reproducibility of manometric criteria for UES incompetence in prevention of pharyngeal reflux. We hypothesize that these criteria are comprised of either a single or constellation of manometric abnormalities. After determining the ability of externally applied cricoid cartilage pressure in preventing pharyngeal reflux, we further hypothesize that this approach will eliminate or reduce esophago-pharyngeal reflux by enhancing the UES pressure barrier. We anticipate there will be a close spatial correlation between the site of applied pressure and area of increased pressure within UES high pressure zone. Lastly, we will determine and characterize the effect of externally applied cricoid cartilage pressure on related functions such as belch and swallow, testing the hypothesis that these functions will not be impaired.

NCT ID: NCT05690022 Not yet recruiting - Clinical trials for Gastroesophageal Reflux

The Use of EndoFlip as a Clinical Tool for the Prediction of Postoperative GERD After Sleeve Gastrectomy

Start date: February 1, 2023
Phase: N/A
Study type: Interventional

This study aims to determine if preoperative EndoFlip measurement can effectively predict postoperative GERD-related quality of life and lower esophageal acid exposure.

NCT ID: NCT05689918 Active, not recruiting - Clinical trials for Gastro Esophageal Reflux

Gastroesophageal Reflux Disease in the Dutch Population

REFLUX
Start date: December 7, 2022
Phase:
Study type: Observational [Patient Registry]

Rationale: Screening for esophageal adenocarcinoma (EAC) precursors and treating them may help to decrease mortality of this malignancy. To understand the size of the target population for potential EAC screening, insight in the prevalence of registered and unregistered individuals with gastro-esophageal reflux disease (GERD) symptoms is needed. Insight in public awareness of EAC will provide additional useful information for public communication strategies. Objective: The aims of this study are to assess the prevalence of GERD symptoms and related help-seeking behavior, registered and unregistered medication use and awareness of esophageal cancer in the general Dutch population. Study design: Cross-sectional population-based survey. Study population: Dutch citizens aged 18-75 years. Methods: Eligible individuals will be selected from the Dutch population registry (BRP) using simple random sampling. Invitations will be sent by postal mail with participants being directed to a digital survey. Main study parameters/endpoints: The outcome variables are presence of current GERD symptoms, number of GERD patients that consulted a doctor, number of GERD patients using prescribed and/or over the counter (OTC) antacids, histamine-receptor antagonists (H2RAs) and proton pump inhibitors (PPIs), and awareness and beliefs about esophageal cancer. The association between socio-demographic background and outcome variables will also be evaluated. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Subjects will not directly benefit from participating in this study. Nonetheless, participating in this study is not associated with any healthcare risks and the burden for the subjects is very low. The survey has a low burdensome nature and will take approximately 20 minutes to complete. All data will be pseudonymized, refusal to fill out the survey or desire to withdraw from the study will not have any consequences for the invited subject.

NCT ID: NCT05678491 Enrolling by invitation - Clinical trials for Gastro Esophageal Reflux Disease

Endoscopic Treatment of Gastroesophageal Reflux Disease

Start date: June 1, 2024
Phase: N/A
Study type: Interventional

Gastroesophageal reflux disease (GERD) occurs when stomach acid repeatedly flows back into the tube connecting your mouth and stomach (esophagus). This backwash (acid reflux) can irritate the inner lining of the esophagus. This is a particular problem after surgery to reduce obesity called gastric sleeve resection. The goal of this small clinical trial is to examine the effect of endoscopic treatment of GERD by mucosal band ligation. The main questions it aims to answer are: - Does the treatment affect gastroesophageal reflux assessed by measuring gastroesophageal reflux - Does the treatment affect gastroesophageal reflux symptoms and ability to stop treatment with medication commonly used (proton pump inhibitors) Participants (n=12) will be asked to undergo 24 h reflux examination and report symptoms of GERD. Suitable patients will be offered endoscopic treatment with band ligation of the inner lining of the lower esophagus and upper part of the stomach. The effects will be assessed three and six months after the procedure.

NCT ID: NCT05660122 Recruiting - Clinical trials for Gastroesophageal Reflux Disease

A Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab

Start date: November 11, 2022
Phase:
Study type: Observational

This observation study is a large-scale, prospective, and multi-organ observation study to observe the improvement effect of the self-evaluation results (PRO) of erosive gastroesophageal reflux disease at least 4 to 8 weeks after administration of Fexuclue Tab.

NCT ID: NCT05647668 Completed - Clinical trials for Gastroesophageal Reflux Disease

Laparoscopic Total vs Partial Fundoplication in Patients With Atypical Symptoms of Gastroesophageal Reflux Disease

Start date: March 1, 2018
Phase: N/A
Study type: Interventional

One hundred and twenty patients with documented extraesophageal symptoms of gastroesophageal reflux disease were randomized to either undergo floppy Nissen (n= 60) or Toupet fundoplication (n= 60). Symptom scores of extraesophageal symotoms and quality of life were prospectively evaluated. Analysis of the treatment results showed a significant improvement of symptoms in both patient groups.Quality of life improved substantially at short- and long-term follow up in both groups and there were no statistical differences between the groups in this parameter.

NCT ID: NCT05634187 Completed - Clinical trials for Reflux, Gastroesophageal

One-stop-shop Endoscopy in Reflux-patients: Evaluation of ENT and GI Features

ENTGI-reflux
Start date: November 20, 2022
Phase:
Study type: Observational

Patients suffering from gastroesophageal reflux may suffer from both esophageal and laryngeal irritations. The investigators developed an endoscopic technique called functional endoscopy to evaluate alterations in the larynx and pharynx as well as in the esophagus simultaneously as one-stop-shop.

NCT ID: NCT05614752 Active, not recruiting - Clinical trials for Gastroesophageal Reflux Disease

Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab

Start date: July 6, 2022
Phase:
Study type: Observational

This observational study is a large-scale, prospective, and multi-institutional observational study. Patients from 19 to 75 years of age, will take a self-assessment (PRO) during the study period before and after administration of Pexuclue tablet.